We read with interest several studies regarding correlated adherence to nucleos(t)ide
analogues treatment with the occurrence of resistance or virological breakthrough(VB)
[
1
,
2
,
3
]. These studies showed that poor adherence was associated with an increased risk
of VB and resistance, with the incidence rate of resistance related to poor adherence
ranging from 5.6 to 50%. These results were quite different. Therefore, we undertook
a study to analyze possible trigger factors in the 926 CHB patients receiving NAs
and VB.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?.J Hepatol. 2011; 55: 1468-1469
- Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.J Hepatol. 2011; 54: 12-18
- Adherence to nucleos(t)ide analogues for chronichepatitis bin clinical practiceandcorrelation with virological breakthroughs.J Viral Hepat. 2012; 19: 205-212
- Chinese medical association. The guideline of prevention and treatment for chronic hepatitis B (2010 version).Chin J Hepatol. 2011; 19: 13-24
- Factors associated with HBV virological breakthrough.Antivir Ther. 2017; 22: 53-60
- Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.J Gastroenterol Hepatol. 2004; 19: 1276-1282
Article info
Publication history
Published online: May 23, 2018
Accepted:
February 14,
2018
Received in revised form:
December 18,
2017
Received:
October 31,
2017
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
